CT-011
Sponsors
CureTech Ltd, Medivation, Inc., M.D. Anderson Cancer Center, Beth Israel Deaconess Medical Center, Augusta University
Conditions
Breast CancerCancer of the PancreasChronic Hepatitis CColon CancerLymphomaLymphoma, Large Cell, DiffuseLymphoma, Mixed Cell, DiffuseMalignant Melanoma
Phase 1
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
TerminatedNCT00962936
Start: 2009-09-30End: 2013-01-31Updated: 2014-08-29
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
TerminatedNCT00966251
Start: 2009-10-31End: 2011-06-30Updated: 2012-10-23
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
WithdrawnNCT01386502
Start: 2011-06-15End: 2011-10-31Updated: 2017-07-02
Phase 2
CT-011 MAb in DLBCL Patients Following ASCT
CompletedNCT00532259
Start: 2007-10-31End: 2011-08-31Updated: 2014-09-12
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
CompletedNCT00890305
Start: 2009-05-31End: 2013-03-31Updated: 2015-07-08
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
CompletedNCT00904722
Start: 2010-01-31End: 2015-04-30Updated: 2016-06-03
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
CompletedNCT01067287
Start: 2010-03-01End: 2025-12-01Target: 35Updated: 2026-04-06
Gemcitabine and CT-011 for Resected Pancreatic Cancer
TerminatedNCT01313416
Start: 2012-09-30End: 2017-01-31Updated: 2019-07-10
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
CompletedNCT01435369
Start: 2011-11-30End: 2013-08-31Updated: 2016-01-21
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
TerminatedNCT01441765
Start: 2011-11-30End: 2016-07-31Updated: 2017-02-08